Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dienogest

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dienogest
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Menorrhagia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Pregnadien derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dienogest in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dienogest with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety Study of an Oral Contraceptive in Healthy Females

    NCT00206583 · start 2005-03

    Registered record
    Registry ID
    NCT00206583
    Conditions
    Contraception
    Interventions
    EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-03
    Completion
    2007-07
    Enrolment
    499

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionEV/DNG (Qlaira, BAY86-5027, SH T00658ID)
    PhasePhase 3
    Registry statusCompleted

  • Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa

    NCT00280657 · start 2004-03-10

    Registered record
    Registry ID
    NCT00280657
    Conditions
    Acne Vulgaris
    Interventions
    Valette; Diane; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-03-10
    Completion
    2005-05-21
    Enrolment
    1,326

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionValette; Diane; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Bleeding Pattern Study

    NCT00302666 · start 2003-06

    Registered record
    Registry ID
    NCT00302666
    Conditions
    Oral Contraceptive
    Interventions
    Valette (Dienogest/EE30, BAY86-5038); Valette (Dienogest/EE30, BAY86-5038)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-06
    Completion
    2005-02
    Enrolment
    1,315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Contraceptive
    InterventionValette (Dienogest/EE30, BAY86-5038); Valette (Dienogest/EE30, BAY86-5038)
    PhasePhase 3
    Registry statusCompleted

  • Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens

    NCT00805415 · start 2003-03

    Registered record
    Registry ID
    NCT00805415
    Conditions
    Ovulation Inhibition
    Interventions
    EV/DNG (Qlaira, BAY86-5027, SH T00658K); EV/DNG (SH T00658L)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-03
    Completion
    2004-02
    Enrolment
    209

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvulation Inhibition
    InterventionEV/DNG (Qlaira, BAY86-5027, SH T00658K); EV/DNG (SH T00658L)
    PhasePhase 2
    Registry statusCompleted

  • Fat Distribution in Healthy Early Postmenopausal Women

    NCT00335218 · start 2002-07

    Registered record
    Registry ID
    NCT00335218
    Conditions
    Healthy; Postmenopause
    Interventions
    Climodien / Lafamme (BAY86-5027); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-07
    Completion
    2004-08
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Postmenopause
    InterventionClimodien / Lafamme (BAY86-5027); Placebo
    PhasePhase 4
    Registry statusCompleted